Drugs Take Backseat to Seeds at Bayer With Monsanto Acquisition

  • Health unit needs to do deals as top-seller faces competition
  • Bayer may lack cash, focus to keep scouting for new medicines

Bayer, Monsanto CEOs on Getting Deal Done

In the wake of its $66 billion-acquisition of Monsanto Co., Bayer AG risks starving its lucrative drugs business of the resources it needs to grow.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.